On July 19, 2021, Adamis Pharmaceuticals Corporation announced that at its annual shareholders meeting held on July 16, 2021, the shareholders of the Company have elected Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, David J. Marguglio, and Richard C. Williams as directors to hold office until the 2022 annual meeting of stockholders, or until such person’s successor is duly elected and qualified, or until such person’s earlier resignation, death, or removal.